Can the Endocannabinoid System Be Measured Like Blood Sugar?

One of the most persistent frustrations in medical cannabis prescribing is the absence of objective tools. Clinicians can measure blood glucose, inflammatory markers, and cardiovascular function, yet they have no practical way of assessing whether a patient's endocannabinoid system is functioning optimally, or whether chronic cannabis exposure has altered receptor availability in ways that affect treatment outcomes. A Swedish researcher believes that gap is now closable — and he has filed a patent to prove it.

A System That Is Foundational but Largely Unmeasured

Dr Stefan Broselid, founder and scientific lead of ECS Restore, has submitted a patent application for a non-cannabinoid formulation designed to treat dysfunction in the endocannabinoid system (ECS) — the network of receptors and signalling molecules that, as Broselid has described to Business of Cannabis, is "foundational to human physiology", playing a "regulatory role in virtually every major system in the body". Despite its broad influence over metabolism, stress responses, pain modulation, and neurological adaptation, the ECS remains one of the least clinically measurable systems in routine medicine.

The receptor at the centre of Broselid's work is CB1, the primary cannabinoid receptor in the central nervous system and peripheral tissues. CB1 participates in signalling networks tied to metabolic regulation, autonomic function, and recovery — yet unlike HbA1c for blood glucose or troponin for cardiac stress, no validated clinical test currently reports CB1 functional state in a way that is useful at the point of care.

The Tolerance Problem Made Measurable

To illustrate why this matters, Broselid points to a well-documented phenomenon in medical cannabis: tolerance. Positron emission tomography (PET) neuroimaging studies have shown that people who consume cannabis daily on a chronic basis display approximately 20% lower CB1 receptor availability compared to non-consumers. Recovery follows a predictable trajectory — initial reversal begins within 48 hours of cessation, with a return to baseline occurring within roughly 28 days.

The clinical implication is significant. Without a practical tool for tracking this dynamic, medical cannabis patients have no objective means of knowing where they sit on that recovery curve at any given point. Most respond to reduced efficacy by increasing their dose — a rational but potentially counterproductive response if declining receptor availability, rather than insufficient dosing, is the underlying issue. Broselid's proposed biomarker is designed to make that distinction possible.

"Medicine advances when biology becomes measurable. We can measure glucose metabolism, cardiovascular fitness and inflammatory markers, but we lack practical tools for understanding functional ECS state." — Dr Stefan Broselid, ECS Restore

A Physiological Fingerprint, Not a Direct Receptor Test

Importantly, Broselid is not proposing to measure CB1 receptors directly — a technically demanding task that currently requires PET imaging facilities. Instead, he is developing what he calls a "physiological fingerprint": a non-invasive biomarker approach that infers changes in CB1-associated function by tracking downstream physiological signals that change in parallel with known CB1 adaptation biology. The hypothesis emerged from a longitudinal self-experiment contrasting physiological states during chronic high-dose THC exposure and a subsequent dose-reduction and washout period, benchmarked against a CB1-intact control condition.

The patent application, according to ECS Restore, includes exploratory supporting data spanning neurodevelopmental, autonomic, and pain-related physiological observations. Broselid acknowledges that the biomarker approach will require formal clinical validation before it can be adopted in prescribing contexts — a standard scientific caveat, but one worth noting given the early-stage nature of the work.

Beyond the patent, Broselid is developing what ECS Restore describes as a longitudinal adaptive-physiology platform. Rather than returning isolated biomarker snapshots, the platform would follow physiological trajectories over time, tracking whether a patient's adaptive capacity — their body's ability to maintain and recover ECS function — is improving, stable, or declining. The commercial vision positions this platform as the longer-term product offering for ECS Restore, sitting alongside the patented formulation itself.

Why This Matters for European Medical Cannabis Prescribing

The practical applications for European medical cannabis programmes are considerable. Across the continent, prescribers working in therapeutic frameworks are largely reliant on subjective patient reporting and clinical observation to guide dosing decisions. Tools that introduce objective, measurable biological data into that process — particularly around tolerance and receptor adaptation — could meaningfully improve prescribing precision and patient safety.

In Malta, where medical cannabis and adult-use cannabis operate as distinct regulatory frameworks under the oversight of ARUC (Authority on the Responsible Use of Cannabis), the question of tolerance and dosing accuracy is already a live issue within the therapeutic community. Healthcare professionals working with medical cannabis patients in Malta, as in much of Europe, currently lack the biological measurement tools that would allow them to distinguish between a patient who needs a dose adjustment and one whose CB1 receptors have downregulated in response to existing consumption patterns. A validated biomarker of the kind Broselid is developing would represent a meaningful addition to that clinical toolkit.

Emerging research also cited by ECS Restore suggests that metabolic signals — including insulin — may regulate CB1 receptor abundance, and that dietary fat quality influences endocannabinoid signalling potential through the lipid substrates from which endocannabinoids are synthesised. If these mechanisms prove robust across insulin-sensitive tissues, it would reframe the ECS as a nutrient-responsive adaptive system rather than simply the biological target of plant-derived cannabinoids — a perspective that could influence not just cannabis medicine, but broader metabolic and neurological research.

The ECS Restore patent application represents an early but meaningful step toward making a largely invisible biological system legible to clinicians and patients alike. Whether the biomarker hypothesis survives formal validation remains to be seen, but the underlying ambition — to bring the endocannabinoid system into the standard toolkit of measurable physiology — addresses a genuine gap that European prescribers and patients have long contended with.

Sources:
Business of Cannabis — "The Company That Wants to Make the Endocannabinoid System as Measurable as Blood Sugar": https://businessofcannabis.com/the-company-that-wants-to-make-the-endocannabinoid-system-as-measurable-as-blood-sugar/

Featured image: Photo by Marek Piwnicki on Pexels